Demand For Cannabis Science Drug Increases As Company Moves Into 2nd Stage Of Protocols For Pre-Clinical Drug Development, Thanks To Positive Laboratory Results From Its Operations In Spain
COLORADO SPRINGS, Colo., Nov. 13, 2014 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce it is moving into 2nd stage cannabinoid production in Spain.
“These events are sparking a much higher demand from the general public regarding access to medical cannabis and information regarding how it can be used to treat various illnesses and disease,” said Raymond C. Dabney, President, CEO, Co-Founder and Director of the company. “We are investigating other significant target cannabinoids for increased production.”
He said the company is also on track to deliver extensive data on CBD and THC levels, along with treatment regimes for many of its targeted ailments.
“Our year-round growing capabilities give us the ability to meet the growing demand based on the number of delivery methods we are developing for various critical ailments,” said Mario S. Lap, Director and President of European Operations. “We will be providing our formulation and developing scalability and portability for our pre-clinical programs that will target GMP production requirements. We’re also setting up other patient groups in Spain and other countries to use formulations we developed.”
The company’s cannabinoid winter production crop is expected to handle its current demand of medications for several targeted ailments. The company is performing 2nd phase experiments and preparing the post-experiment production grow to start early 2015.
The previous testing of the harvested cannabis, which included EU-certified crops as well as the company’s own unique strains, produced end results indicating that its whole extracts produced unique identifiers that require multiple authentications based on their significant nature.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder